S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Critical asset just had biggest fall on record (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Critical asset just had biggest fall on record (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:STSA

Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.01
$1.14
50-Day Range
$1.04
$1.11
52-Week Range
$0.59
$8.08
Volume
1.83 million shs
Average Volume
701,788 shs
Market Capitalization
$36.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Satsuma Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
127.3% Upside
$2.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.82) to ($0.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

Medical Sector

391st out of 936 stocks

Pharmaceutical Preparations Industry

175th out of 422 stocks


STSA stock logo

About Satsuma Pharmaceuticals Stock (NASDAQ:STSA)

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.


STSA Stock News Headlines

Satsuma City High School
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Japanese pharma acquires its Durham spin-out
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
STSA Satsuma Pharmaceuticals, Inc.
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
SNBL to Acquire Satsuma Pharmaceuticals
8-K: Satsuma Pharmaceuticals, Inc.
STSA.O
See More Headlines
Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Current Symbol
NASDAQ:STSA
CUSIP
85931930
Fax
N/A
Employees
21
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+127.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-70,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.41 per share

Miscellaneous

Free Float
22,809,000
Market Cap
$36.47 million
Optionable
Not Optionable
Beta
0.10

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. John A. Kollins MBA (Age 59)
    Pres, CEO & Director
    Comp: $830k
  • Mr. Thomas P. O'Neil (Age 57)
    Chief Financial Officer
    Comp: $550.08k
  • Dr. Detlef F. Albrecht (Age 61)
    Chief Medical Officer
    Comp: $625.97k
  • Mr. Mic Iwashima (Age 44)
    VP & Head of Operations
  • Mr. Robert Schultz (Age 58)
    Sr. VP & Head of Chemistry, Manufacturing and Controls
  • Dr. Shannon Strom Ph.D. (Age 46)
    VP & Head of Regulatory Affairs
  • Mr. Robert M. Janosky
    Chief Commercial Officer














STSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Satsuma Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" STSA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STSA, but not buy additional shares or sell existing shares.
View STSA analyst ratings
or view top-rated stocks.

What is Satsuma Pharmaceuticals' stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Satsuma Pharmaceuticals' stock. Their STSA share price targets range from $2.00 to $3.00. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 127.3% from the stock's current price.
View analysts price targets for STSA
or view top-rated stocks among Wall Street analysts.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) issued its earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

This page (NASDAQ:STSA) was last updated on 2/26/2024 by MarketBeat.com Staff